A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies

[1] Arango C(2020)Lessons learned from the coronavirus health Crisis in Madrid, Spain: how COVID-19 has changed our lives in the last 2 weeks Biol Psychiatry 88 e33-e34

[2] Henkens MTHM(2022)Age is the main determinant of COVID-19 related in-hospital mortality with minimal impact of pre-existing comorbidities, a retrospective cohort study BMC Geriatr 89 780-789

[3] Raafs AG(2022)A multiparametric score for assessing the individual risk of severe COVID-19 among patients with Multiple Sclerosis Mult Scler Relat Disord 386 2436-2438

[4] Verdonschot JAJ(2022)Severe outcomes of COVID-19 among patients with multiple sclerosis under anti-CD-20 therapies: a systematic review and meta-analysis Mult Scler Relat Disord 7 eabo1303-492

[5] Ponzano M(2022)Seroprevalence of SARS-CoV-2 in a cohort of patients with multiple sclerosis under disease-modifying therapies J Clin Med 603 488-462

[6] Schiavetti I(2021)Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis Ann Neurol 584 457-2001

[7] Bovis F(2022)Global impact of the first year of COVID-19 vaccination: a mathematical modelling study Lancet Infect Dis 18 284-173

[8] Schiavetti I(2022)A detailed overview of immune escape, antibody escape, partial vaccine escape of SARS-CoV-2 and their emerging variants with escape mutations Front Immunol 27 1990-849

[9] Ponzano M(2022)SARS-CoV-2 evolution and immune escape in immunocompromised patients N Engl J Med 17 162-2292

[10] Signori A(2022)Understanding T cell responses to COVID-19 is essential for informing public health strategies Sci Immunol 122 841-971

[1] Arango C(2020)Lessons learned from the coronavirus health Crisis in Madrid, Spain: how COVID-19 has changed our lives in the last 2 weeks Biol Psychiatry 88 e33-e34

[2] Henkens MTHM(2022)Age is the main determinant of COVID-19 related in-hospital mortality with minimal impact of pre-existing comorbidities, a retrospective cohort study BMC Geriatr 89 780-789

[3] Raafs AG(2022)A multiparametric score for assessing the individual risk of severe COVID-19 among patients with Multiple Sclerosis Mult Scler Relat Disord 386 2436-2438

[4] Verdonschot JAJ(2022)Severe outcomes of COVID-19 among patients with multiple sclerosis under anti-CD-20 therapies: a systematic review and meta-analysis Mult Scler Relat Disord 7 eabo1303-492

[5] Ponzano M(2022)Seroprevalence of SARS-CoV-2 in a cohort of patients with multiple sclerosis under disease-modifying therapies J Clin Med 603 488-462

[6] Schiavetti I(2021)Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis Ann Neurol 584 457-2001

[7] Bovis F(2022)Global impact of the first year of COVID-19 vaccination: a mathematical modelling study Lancet Infect Dis 18 284-173

[8] Schiavetti I(2022)A detailed overview of immune escape, antibody escape, partial vaccine escape of SARS-CoV-2 and their emerging variants with escape mutations Front Immunol 27 1990-849

[9] Ponzano M(2022)SARS-CoV-2 evolution and immune escape in immunocompromised patients N Engl J Med 17 162-2292

[10] Signori A(2022)Understanding T cell responses to COVID-19 is essential for informing public health strategies Sci Immunol 122 841-971